IMPORTANT NOTICE: AATB Standards are subject to revision at any time pursuant to the Association’s procedures. Such revisions may consist of the addition of a new Standard, the rescission of an existing Standard, and/or the partial amendment of a Standard. Notice of each such revision is given by AATB by posting on the Association’s website, and distributing via email, a “Bulletin” that announces those changes and their respective effective dates. Persons seeking to determine the current provisions of Standards should always review the Bulletins for any such announcement of revisions to Standards or may request a current and effective copy of the Standards by sending a request to the AATB mailbox: email@example.com. Please contact AATB's headquarters office for any questions concerning Standards or revisions thereof.
Published on: December 16, 2019
The Board of Governors acted on recommendation from the Standards Committee and approved a second six-month extension of the effective date of Section B1.500 Written Agreements/Contracts and B2.210 Qualifications as amended and announced originally on January 31, 2019, in AATB Bulletin #19-1 with a subsequent extension announced on July 9, 2019, in AATB Bulletin # 19-5.
Published on: July 31, 2019
The Board of Governors acted on recommendation from the Standards Committee and approved changes to the 14th Edition (2016) of AATB's Standards for Tissue Banking and the 2nd Edition of the AATB Standards for Non-Transplant Anatomical Donation (NTAD).
Published on: July 09, 2019
The Board of Governors has acted on a recommendation from the Standards Committee and approved a Resolution for a six-month extension of the effective date of previously approved changes to Standards B1.500 Written Agreements/Contracts and B2.210 Qualifications. The amendments had been announced in AATB Bulletin #19-1 on January 31, 2019, and have been known as the Medical Director’s Role Amendments.
Published on: June 13, 2019
On June 12, 2019, the FDA notified the American Association of Tissue Banks (AATB) about the new TRG Rapid Inquiry Program (TRIP) page published on the FDA website.